Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Expert Rev Clin Pharmacol. 2022 Oct;15(10):1233-1242. doi: 10.1080/17512433.2022.2120469. Epub 2022 Sep 7.
Dupilumab is approved for multiple type 2 inflammatory diseases. In the treatment procedure, the changes of IgE levels need further analysis. We evaluated the changes of IgE levels through meta-analysis, aiming to provide a more comprehensive result.
Databases were searched to select eligible publications. After being included, study quality was assessed. The standardized mean difference (SMD) was used as an evaluation.
Seven studies were included. At week 4, the level of IgE did not decrease significantly, with SMD = -0.12 (95%CI: -0.31, 0.07) ( > 0.05). At week 8, 12, 16, 24, and 52, the level of IgE decreased significantly, which was SMD = -0.26 (95%CI: -0.48, -0.03); -0.25 (95%CI: -0.32, -0.18); -0.49 (95%CI: -0.65, -0.33); -0.30 (95%CI: -0.38, -0.22); -0.40 (95%CI: -0.48, -0.32) ( < 0.05). In AD studies, with the increase of IgE levels, due to the decrease in the total dose of dupilumab, the efficacy index showed a decreasing trend.
Levels of IgE can be significantly decreased in patients with dupilumab treatment. In AD patients, the efficacy was related to total dose; for patients with high IgE levels, efficacy may be better with the dose increased.
度普利尤单抗获批用于多种 2 型炎症性疾病。在治疗过程中，需要进一步分析 IgE 水平的变化。我们通过荟萃分析评估 IgE 水平的变化，旨在提供更全面的结果。
检索数据库以选择合格的出版物。纳入后，评估研究质量。使用标准化均数差（SMD）作为评估。
纳入 7 项研究。第 4 周时，IgE 水平没有显著下降，SMD=-0.12（95%CI：-0.31，0.07）（>0.05）。第 8、12、16、24 和 52 周时，IgE 水平显著下降，SMD=-0.26（95%CI：-0.48，-0.03）；-0.25（95%CI：-0.32，-0.18）；-0.49（95%CI：-0.65，-0.33）；-0.30（95%CI：-0.38，-0.22）；-0.40（95%CI：-0.48，-0.32）（<0.05）。在 AD 研究中，随着 IgE 水平的升高，由于度普利尤单抗总剂量的减少，疗效指数呈下降趋势。
度普利尤单抗治疗可显著降低患者 IgE 水平。在 AD 患者中，疗效与总剂量相关；对于 IgE 水平较高的患者，增加剂量可能会有更好的疗效。
